Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 23, 2019 - Pfizer announced the FDA approval of Ruxience (rituximab-pvvr), a biosimilar to Genentech/Biogen’s Rituxan® (rituximab).
Download PDF
Return to publications
